Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + Gedatolisib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, Ovarian Cancer
Trial Timeline
Dec 24, 2018 → Aug 1, 2031
NCT ID
NCT03675893About Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + Gedatolisib
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + Gedatolisib is a phase 2 stage product being developed by eFFECTOR Therapeutics for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03675893. Target conditions include Endometrial Cancer, Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03675893 | Phase 2 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer